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Predictors of Surgery and Consult with an Oncologist for
Adjuvant Chemotherapy in Early Stage NSCLC Patients in
Alberta, Canada
Marcy Winget, PhD,*† Jennifer Stanger, MD,† Zhiwei Gao, MSc,* and Charles Butts, MD*
Introduction: In the fall of 2004, adjuvant chemotherapy for early
stage non-small cell lung cancer (NSCLC) patients was approved for
coverage by the Alberta Cancer Board, the provincial agency re-
sponsible for systemic therapy in the province of Alberta. The
purpose of this study was to measure the proportion of early stage
NSCLC patients diagnosed between 2004 and 2006 that received
surgery and subsequently had a consult with an oncologist at a
cancer facility, and to identify factors related to receiving surgery
and having a consult that could be addressed.
Methods: A retrospective observational study was conducted. All
patients diagnosed with stage IB, IIA, or IIB NSCLC in Alberta
from 2004 to 2006 were identified from the Alberta cancer registry.
Date of definitive surgery, gender, age at diagnosis, and area of
residence were also obtained from the cancer registry and evaluated
as predictors for surgery and oncology consult. Date of consult with
an oncologist was obtained from the electronic medical record of the
Alberta Cancer Board.
Results: There were 561 patients diagnosed with stage IB–IIB NSCLC
from 2004 to 2006, 352 of whom had surgery and 255 of whom
subsequently had a consult with an oncologist. Age and residence at
diagnosis were both strongly associated with the likelihood of receiving
surgery and the likelihood of attending a consult with an oncologist.
Discussion: Several areas of further research have been identified by
this study including age and rural residence on treatment/referral
patterns.
Key Words: Early stage NSCLC, Surgery, Oncology, Consultation,
Adjuvant chemotherapy.
(J Thorac Oncol. 2009;4: 629–634)
Approximately 80% of lung cancers are classified as non-small cell, which includes squamous carcinoma, large-
cell carcinoma, and adenocarcinoma.1 Of these, 25% are
considered to be early stage tumors (including stage IB, IIA,
IIB) at the time of diagnosis.2 In the fall of 2004, two
combination chemotherapy regimens were approved for full
coverage in Alberta for stage IB, IIA, and IIB non-small cell
lung cancer (NSCLC) patients. This decision was based on
the review of several clinical trials.3,4 Five-year survival in
the patients who received adjuvant therapy was improved by
4 to 15% over surgery alone in these clinical trials.
There are many issues that are discussed, in addition to
survival, when determining whether a drug should be approved
for coverage. The number of patients to benefit, the cost of the
drug per patient, and the total annual cost are a few. It is,
therefore, important to have good estimates for these factors
during the review of the drug and after the approval to determine
whether the effect on patient care and costs were as expected or
whether interventions, to optimize patient care or modify costs,
are needed. In this study, we focus on aspects of patient care and
factors that might relate to access and uptake to the newly
approved regimen for early stage NSCLC.
Uptake of a new treatment is a function of several
factors, including patient-specific and clinician-specific char-
acteristics.1,5,6 In order for a patient to be eligible for one of
the adjuvant chemotherapy regimens approved in 2004 in
Alberta, they must have stage IB, IIA, or IIB NSCLC (cov-
erage for stage IIIA patients occurred prior to 2004), have had
surgery with negative margins, and be able to begin chemo-
therapy within 12 weeks of the surgery. In order for a patient
to receive adjuvant chemotherapy, therefore, he/she must
receive surgery and then be referred to a cancer facility for a
consult with an oncologist. Other than patient choice, receipt
of surgery and referral to an oncologist are, therefore, the key
factors external to the Alberta Cancer Board (ACB) that
effect uptake of adjuvant chemotherapy.
In Alberta, all cancer care except surgery is provided by
the ACB via two tertiary facilities and several smaller facil-
ities throughout the province. Surgery is provided by fellow-
ship trained thoracic surgeons in tertiary care centers located
in Edmonton or Calgary. Although thoracic surgeons are not
employed by the ACB, they are an integral part of a team
approach with oncologists for discussing and approving new
drug therapies and treatment guidelines for lung cancer pa-
tients. In Calgary, the clinics which patients attend for con-
sults with the surgeons before their surgery are held within
the cancer facility, whereas in Edmonton they are held at
other tertiary hospitals. The proximity of clinics in Calgary
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between surgeons and oncologists creates a particularly good
environment for team care.
The purpose of this study was to measure the propor-
tion of early stage NSCLC patients diagnosed between 2004
and 2006 who received surgery and subsequently had a
consult with an oncologist at a cancer facility and identify
factors that were associated with having surgery and subse-
quent consult with an oncologist that could potentially be
addressed by the ACB to improve access to care.
METHODS
All residents of Alberta who were diagnosed in 2004,
2005 and 2006 with stage IB, IIA, or IIB NSCLC were
identified from the Alberta Cancer Registry and included in
the study. Patients were excluded if they were not residents of
Alberta, had another cancer diagnosis within 6 months of the
lung cancer, or did not have stage IB, IIA or IIB disease.
Gender, postal code at diagnosis, age at diagnosis, and date of
surgery for curative intent were also obtained from the
Alberta Cancer Registry. A conversion table was used to
determine residence by Regional Health Authority (RHA) at
time of diagnosis from the postal code. In Alberta, medical
care, other than cancer care, is coordinated through nine
RHAs (Figure 1). There is large variation across RHAs with
respect to the number and types of specialists available
locally (such as pulmonologists) which may impact referral
patterns and ultimately the type of care and/or timeliness of
care patients receive. RHA was, therefore, examined as a
predictive factor for both outcomes of interest: surgery and
consult with an oncologist.
The Alberta Cancer Registry is routinely recognized by
the North American Association of Comprehensive Cancer
Registries for the completeness and timeliness of its data
reporting. Since 1997 North American Association of Com-
prehensive Cancer Registries has administered a program that
annually reviews member registries for their ability to pro-
duce complete, accurate, and timely data. Each year, mem-
bers of the Data Evaluation and Certification Committee
evaluate cancer incidence data for the most recent data year,
based on predetermined registry certification criteria estab-
lished by the Committee.7 The Alberta Cancer Registry is
regularly awarded the highest level of certification for the
quality of its data.
Chemotherapy for lung cancer patients in Alberta is
only available within ACB facilities, therefore, consults with
oncologists to identify a treatment plan, occur in ACB facil-
ities. The date of the consult with an oncologist was extracted
from the electronic medical record of the ACB. We are not
able to identify situations in which a patient is referred to an
oncologist but does not have a consult scheduled; that is,
instances in which the patient refuses to see an oncologist, but
we are able to identify whether a consult with an oncologist
occurred. If a referral was made but the patient did not attend
the consult, by default, the case was categorized as not having
had a consult. The electronic medical record has been in place
since 2002 and is used for all appointment scheduling for
ACB facilities.
Analyses were conducted using SAS. Percentages were
calculated to describe the population for each categorical
variable of interest. Univariate analyses were conducted us-
ing 2 tests for each outcome. Multiple logistic regression
was performed to obtain estimates for odds ratios, 95%
confidence intervals, and corresponding p-values for vari-
ables that were significant in the univariate analyses.
RESULTS
There were 592 stage IB–IIB NSCLC patients identi-
fied from the Alberta Cancer Registry who were diagnosed in
the years 2004, 2005, and 2006. There were 24 nonresidents
of Alberta, two multiple cancer cases (bladder, kidney), two
cases who had pretreatment with chemo, one case who has
never come to ACB for consult or treatment, one case with
positive cytology but no mass seen in surgery, and one case
who upon further review was found to have metastases who
were excluded from this study, leaving 561 that were in-
cluded. Table 1 shows the distribution of all patients, by
stage, age, gender, year of diagnosis, and health region of
residence at time of diagnosis. Due to small numbers of
patients in certain regions, some health regions were com-
bined as indicated in Table 1. The median age at diagnosis
FIGURE 1. Map of Alberta showing the boundaries of the
nine health regions and facilities of the Alberta Cancer Board
(ACB).
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was 70 years, most patients had stage IB disease (70%), and
slightly more than half were men. Figure 1 is a map of
Alberta showing the geographical boundaries of the RHAs
and the locations of the different types of ACB facilities.
Almost 70% of patients resided in one of the two RHAs that
contain the only two tertiary cancer facilities in the province,
Calgary and Edmonton.
Of the 561stage IB–IIB NSCLC patients, 165 (29%)
did not receive surgery but were referred to an ACB facility
for a consult with an oncologist, 44 (8%) did not receive
surgery or have a consult with an oncologist, and 352 (63%)
of them had surgery. Neither stage at diagnosis nor gender
was associated with having surgery (Table 1). Age at diag-
nosis was significantly associated with surgery (p 0.001)
with younger patients incrementally more likely to receive
surgery than older patients. Residence of RHA at diagnosis
was marginally associated with surgery (p  0.077) with
those in the southern/central parts of the province least likely
to receive surgery (Table 1). All except 47 patients had
microscopically confirmed stage IB–IIB disease, 38 of whom
did not receive any sort of treatment and nine of whom
received radiation only. Results of the univariate analysis and
the multiple logistic regression remained the same when these
patients were excluded.
Of the 352 patients who had surgery, 255 (72%) of
them subsequently had a consult with an oncologist (Table 1).
Age at diagnosis was the factor most strongly associated with
having a consult with an oncologist. Younger patients were
much more likely to have a consult with an oncologist
postsurgery than older patients; 81% of those under age 65
had a consult but only 45% of those age 75 or more (p  
0.001) did. Women (79%) were more likely than men (67%)
to have an oncology consult (p  0.011). Residence at
diagnosis was associated with having a consult with an
oncologist after surgery: patients living in RHA 3 (76%) and
4 (92%) were most likely to have a consult with an oncologist
and patients in RHA 8 and 9 (43%) were least likely (p 
0.028). Year of diagnosis was not associated with receiving
surgery but was associated with receiving a consult with an
oncologist (p  0.011).
Tables 2 and 3 show the results of the multiple logistic
regression models for factors predicting surgery and having a
consult with an oncologist, respectively. Age and RHA of
residence were significantly associated with both receipt of
surgery and consult with an oncologist. Residents living in
southern and central Alberta were less likely to have surgery
than those in northern Alberta, but residents in the far north
were least likely to have a consult with an oncologist subse-
quent to surgery. Year of diagnosis was strongly associated
with receiving a consult with an oncologist, with patients
diagnosed in 2005 being most likely to have an oncology
consult (p  0.006).
TABLE 2. Odds Ratios for Factors Related to Receiving
Surgery for Stage IB–IIB NSCLC Patients Diagnosed in
Alberta in 2004–2006
Odds Ratio
(95% CI)a pb Overall p
Age 0.001
75 1.0
65–74 3.5 (2.3–5.5) 0.001
65 13.3 (7.8–22.7) 0.001
RHAc of residence 0.027
6 1.0
1 or 2 0.5 (0.2–1.1) 0.084
3 0.6 (0.4–1.0) 0.050
4 0.3 (0.2–0.7) 0.002
5 1.5 (0.6–3.8) 0.430
7 0.8 (0.3–2.0) 0.670
8 or 9 0.9 (0.3–2.4) 0.777
Year at diagnosis 0.090
2006 1.0
2004 1.1 (0.7–1.8) 0.717
2005 0.7 (0.4–1.0) 0.091
a 95% confidence interval of the odds ratio.
b p value is based on comparison to reference group.
c Regional Health Authority.
NSCLC, non-small cell lung cancer; RHA, Regional Health Authority.
TABLE 1. Distribution of Early Stage NSCLC Patient
Characteristics by Whether They Had Surgery and Whether







No. (%)b p No. (%)c p
Total 561 (100) 352 (63) 255 (72)
Stage 0.239 0.017
IB 395 (70) 254 (64) 175 (69)
II 166 (30) 98 (59) 80 (82)
Gender 0.929 0.011
Male 302 (54) 190 (63) 127 (67)
Female 259 (46) 162 (63) 128 (79)
Age 0.001 0.001
64 191 (34) 166 (87) 135 (81)
65–74 187 (33) 120 (64) 90 (75)
75 183 (33) 66 (36) 30 (45)
RHAd of residence 0.077 0.028e
1 or 2 42 (7) 24 (57) 15 (63)
3 190 (34) 108 (57) 82 (76)
4 49 (9) 26 (53) 24 (92)
5 33 (6) 25 (76) 18 (72)
6 192 (34) 132 (69) 95 (72)
7 33 (6) 23 (70) 15 (65)
8 or 9 22 (4) 14 (64) 6 (43)
Year at diagnosis 0.107 0.011
2004 174 (31) 116 (67) 74 (64)
2005 200 (36) 114 (57) 93 (82)
2006 187 (33) 122 (65) 88 (72)
a The sum might not be 100 due to rounding.
b The denominator for the percentage is the total number of patients diagnosed in
the given category.
c The denominator for the percentage is the number of patients who had surgery in
the given category.
d Regional Health Authority.
e Exact p value.
NSCLC, non-small cell lung cancer; RHA, Regional Health Authority.
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DISCUSSION
The overall percentage of stage IB–IIB NSCLC pa-
tients who received surgery who were diagnosed between
2004 and 2006 was 63%. This is comparable to surgical rates
reported in other studies, which range from 28 to 85%.2,6,8
Other studies have found that roughly 25 to 30% of early
stage NSCLC patients are not eligible for or decline surgery
for various reasons.6 Reasons for not conducting surgery
include medical comorbidities, patient preference, and loca-
tion of tumor. These factors were not addressed in this study.
Of the 209 patients who did not have surgery, however, 109
(52%) did receive some other sort of treatment, primarily
radiation (105). Based on further review, of those patients who
received radiation but did not have surgery, 43 received pallia-
tive doses suggesting, although originally diagnosed with early
stage disease, they may have had a rapidly growing tumor that
became unresectable and/or metastatic. Given the relatively
large percentage of patients who received palliative radiation,
further investigation of treatment and rate of progression for
early stage lung cancer is warranted. It is likely that the remain-
ing 66 patients who received chemotherapy and/or higher dose
radiation had unresectable tumors or refused surgery.
A significant decrease in surgical resection and decreased
likelihood of consult with an oncologist was seen with increas-
ing patient age. Patients under the age of 65 were more likely to
have surgery than those over 75 (OR 13.3, 95% CI: 7.8–22.7)
and more likely to have a consult with an oncologist (OR 5.1,
95% CI: 2.6–9.9). Similarly, many studies have shown that
older patients are less likely to receive surgery and adjuvant
chemotherapy than younger patients. Reasons for this have
been due to less willingness to accept possibility of toxicity
for small perceived survival benefits, concerns related to quality
of life, prolonged recovery postoperatively, and shorter life
expectancy.9–11 It was not possible in this study to determine
if the lower proportion of older patients having a consult with
an oncologist is due to patient choice not to attend the consult
or clinician’s choice not to refer the patient. Further investi-
gation into this is warranted as there is mounting evidence
that less aggressive treatment of older patients is common,
however, it is less clear as to whether or not less aggressive
treatment is appropriate.12–14
Our study demonstrated significant temporal trends in
having a consult with an oncologist for treatment of localized
NSCLC postsurgery in Alberta. About 64% of patients diag-
nosed in 2004 who had surgery also had a consult to discuss
adjuvant chemotherapy versus 82% in 2005, likely reflecting
a delay in the implementation and uptake of the policy change
regarding adjuvant chemotherapy for these patients. Interest-
ingly, in 2006 there was a decline in the percentage of
patients having a consult for adjuvant chemotherapy postsur-
gery. Table 4 shows the percentage of patients who had
surgery and those who had surgery and consult with an
oncologist by year and tumor stage. The overall decline in
oncology consults in 2006 is due to a decrease in the per-
centage of stage IB patients that had a consult. The percent-
TABLE 4. Percentage of Patients Who Received Surgery and Consult with an Oncologist
by Year and Stage of Diagnosis
Year of Diagnosis
Surgery (n  352) Surgery  Consult (n  255)
2004 2005 2006 2004 2005 2006
No. (%) No. (%) No. (%) No. (%)a No. (%)a No. (%)a
AJCC stage
IB 86 (67) 79 (55) 89 (72) 49 (57) 65 (82) 61 (69)
II 30 (65) 35 (61) 33 (52) 25 (83) 28 (80) 27 (82)
Total 116 (67) 114 (57) 122 (65) 74 (64) 93 (82) 88 (72)
a Denominator for the percent is the number of patients who received surgery in the corresponding AJCC stage category.
AJCC, American Joint Committee on Cancer.
TABLE 3. Adjusted Odds Ratios for Having a Consult with an
Oncologist of Those Stage IB–IIB NSCLC Patients Diagnosed in
Alberta in 2004–2006 Who Had Surgery
Odds Ratio
(95% CI)a pb Overall p
Age 0.001
75 1.0
65–74 3.7 (1.9–7.4) 0.001
64 5.1 (2.6–9.9) 0.001
Gender 0.076
Male 1.0
Female 1.6 (0.9–2.8) 0.078
AJCC stage 0.014
IB 1.0
II 2.2 (1.1–4.1) 0.018
RHAc of residence 0.038
6 1.0
1 or 2 0.7 (0.3–1.9) 0.510
3 1.3 (0.7–2.5) 0.355
4 3.6 (0.8–16.4) 0.104
5 1.5 (0.5–4.2) 0.463
7 0.6 (0.2–1.6) 0.303
8 or 9 0.2 (0.1–0.8) 0.026
Year at diagnosis 0.006
2006 1.0
2004 0.7 (0.4–1.2) 0.207
2005 2.0 (1.0–3.8) 0.051
a 95% confidence interval of the odds ratio.
b p value based on comparison to the reference group.
c Regional Health Authority.
NSCLC, non-small cell lung cancer; RHA, Regional Health Authority.
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age of stage II patients who received an oncology consult
remained fairly constant over the study period. The change in
percentage of stage IB patients having a consult with an
oncologist likely reflects ongoing uncertainty in the manage-
ment of these patients and changes in treatment policy that
occurred in 2006. At the 2006 ASCO meeting several ab-
stracts were presented that suggested not only decreased
efficacy but also potential harm of adjuvant chemotherapy in
stage IB NSCLS patients.15,16 As a follow-up to this meeting,
in 2007 Cancer Care Ontario presented another update and
review of the evidence for adjuvant chemotherapy in
NSCLC.17 The revised guidelines no longer recommend ad-
juvant therapy for patients with stage IB tumors.
Another phenomenon observed in this study was the
variation for both surgery and subsequent consult with an
oncologist by area of residence. Patients living in southern
and central Alberta were less likely to have surgery than those
living in northern Alberta, (56 versus 69%, respectively) but
more likely to have a consult with an oncologist post surgery
(79 versus 72%, respectively). The difference in surgeries is
an unexpected finding and requires further investigation. The
patient population in terms of demographics is comparable
across the province and there is no reason to think that
comorbidities or other factors that would prevent surgery for
medical reasons would differ regionally. It is possible that the
lower proportion of patients who received surgery in central
and southern Alberta is due to issues related to referral
patterns and/or access to the surgeons themselves; reasons for
the regional differences will be investigated.
The higher proportion of patients who had a consult
with an oncologist postsurgery in central and southern Al-
berta than in northern Alberta is a bit surprising, although
there are some reasonable explanations. The thoracic sur-
geons in the south work literally side-by-side the medical
oncologists during patient consults. The higher degree of
face-to-face interactions between specialties may lead to
higher referral rates; we plan to investigate this possibility.
Additionally, the regions with the lowest proportion of pa-
tients that had a consult with an oncologist after surgery were
those in the far north (RHAs 8 and 9). These regions are very
rural and there is only one facility within either of these
regions that provides both treatment planning and delivery of
chemotherapy. Most patients living in these regions, there-
fore, have very long commutes with respect to both time and
distance to attend a consult with an oncologist and ultimately
receive chemotherapy. The ACB has implemented a tele-
health program to overcome distance barriers and increase
access to oncologists. This year we will also pilot a home
chemotherapy administration program to further address ac-
cess issues for patients living in rural/remote areas.
There are two main limitations of this study, First, we
are not able to determine whether patients did not receive
surgery because they were not referred to a surgeon, they
were referred but deemed inoperable (e.g., comorbidities),
had poor tumor location, or patient refusal. We did conduct a
chart review on a subset of patients to determine if we could
obtain high-quality data on comorbidities but found that we
could not. The comorbidity data we abstracted did not help
predict surgery or subsequent consult with an oncologist nor
did it change the effect of age or region of residence when
evaluated via multiple logistic regression models. With the
exception of referral to a surgeon, however, none of the above
factors should differ by region, therefore, the lack of infor-
mation on these factors does not impact the study conclu-
sions. We do plan to investigate whether differences in
surgical rates by region have continued and, if so, whether
they are related to differences in referral rates to surgeons.
Second, we are not able to determine if the reason patients did
not have a consult with an oncologist postsurgery is due to
lack of referral from the surgeon or is due to patient refusal.
Further investigations to determine the reasons are warranted
to optimize access to and receipt of recommended treatment.
Overall, this study demonstrated comparable rates of sur-
gical resection as found in other studies and fairly high rates of
consult with an oncologist for patients with stage IB, IIA, and
IIB NSCLC diagnosed in the province of Alberta soon after the
approval of adjuvant chemotherapy for these patients. The stron-
gest demographic factor affecting surgical resection and referral
for adjuvant chemotherapy is age. Patients older than 75 were
significantly less likely than younger patients to have surgery for
early stage NSCLC. Of those undergoing resection, older pa-
tients were also significantly less likely to have a consult with an
oncologist to discuss adjuvant chemotherapy. Future efforts
should focus on whether these decisions are primarily patient
preference or related to other factors such as comorbidities or
physician perception regarding patient age. Although definitive
referral and treatment patterns were not addressed in this study,
significant regional variation was observed for both surgery and
oncology consults. The information learned by the study is
helpful for future planning and for identifying future areas of
research.
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